Nautilus Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Nautilus Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
SEATTLE, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single-molecule proteome analysis platform, today announced the company will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York.
2024年8月14日，华盛顿，全球货币新闻社报道：鹦鹉螺体育公司（纳斯达克：NAUT，以下简称“Nautilus”）是一家开拓性的单分子蛋白质组分析平台公司，今天宣布该公司将参加摩根士丹利第22届全球医疗保健大会，地点在纽约。
Nautilus management is scheduled to participate in a fireside chat on Wednesday, September 4, 2024, at 7:00 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: .
鹦鹉螺体育管理层计划于2024年9月4日上午7:00（美国东部时间）进行炉边谈话。有兴趣的各方可以在公司网站的“投资者”部分上访问演示文稿的实况和存档网络广播。
About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus' mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit .
关于Nautilus Biotechnology，Inc。
Nautilus位于华盛顿州西雅图市的公司总部和位于加利福尼亚州San Carlos的研究和开发总部，是一家开发阶段的生命科学公司，致力于创建平台技术以量化和解锁蛋白质组的复杂性。 鹦鹉螺体育的使命是通过民主化蛋白质组的获取，并促进在人类健康和医学方面的基本进展，从而改变蛋白质组学领域。 要了解更多关于鹦鹉螺体育，请访问.
Media Contact
press@nautilus.bio
媒体联系人
press@nautilus.bio
Investor Contact
investorrelations@nautilus.bio
投资者联系方式
investorrelations@nautilus.bio
